All patients
age >= 60 yr autoimmune disease invasive ventilation no oxygen needed non invasive oxygen
corticosteroids in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Jamaati, 2021 1.19 [0.38; 3.72]
Metcovid, 2020 0.92 [0.67; 1.28]
Tang X, 2020 0.98 [0.93; 1.02]
0.98 [0.93 ; 1.02 ] Jamaati, 2021, Metcovid, 2020, Tang X, 2020 3 0% 529 moderate not evaluable deathsdetailed results CAPE-COVID, 2020 0.45 [0.20; 1.02]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
Jamaati, 2021 1.19 [0.38; 3.72]
Metcovid, 2020 0.92 [0.67; 1.28]
Ranjbar, 2021 0.40 [0.15; 1.08]
RECOVERY dexamethasone, 2020 0.83 [0.75; 0.92]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
Tang X, 2020 0.98 [0.93; 1.02]
0.90 [0.80 ; 1.01 ] CAPE-COVID, 2020, CODEX (Tomazini), 2020, DEXA-COVID19, 2020, Jamaati, 2021, Metcovid, 2020, Ranjbar, 2021, RECOVERY dexamethasone, 2020, Steroids-SARI, 2020, Tang X, 2020 9 44% 7,553 moderate not evaluable clinical deteriorationdetailed results CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
Tang X, 2020 1.00 [0.13; 7.45]
0.67 [0.44 ; 1.03 ] CODEX (Tomazini), 2020, Tang X, 2020 2 0% 385 moderate not evaluable clinical improvementdetailed results Tang X, 2020 1.04 [0.67; 1.62]
1.04 [0.67 ; 1.62 ] Tang X, 2020 1 0% 86 NA not evaluable clinical improvement (14-day)detailed results Tang X, 2020 1.33 [0.57; 3.11]
1.33 [0.57 ; 3.11 ] Tang X, 2020 1 0% 86 NA not evaluable clinical improvement (time to event analysis only)detailed results Tang X, 2020 1.04 [0.67; 1.62]
1.04 [0.67 ; 1.62 ] Tang X, 2020 1 0% 86 NA not evaluable death or ventilationdetailed results CAPE-COVID, 2020 0.71 [0.37; 1.35]
RECOVERY dexamethasone, 2020 0.92 [0.84; 1.01]
0.92 [0.84 ; 1.00 ] CAPE-COVID, 2020, RECOVERY dexamethasone, 2020 2 0% 5,567 moderate not evaluable hospital dischargedetailed results CAPE-COVID, 2020 1.67 [0.87; 3.19]
RECOVERY dexamethasone, 2020 1.10 [1.03; 1.17]
1.19 [0.86 ; 1.64 ] CAPE-COVID, 2020, RECOVERY dexamethasone, 2020 2 37% 6,574 moderate not evaluable mechanical ventilationdetailed results CAPE-COVID, 2020 0.95 [0.44; 2.04]
Jamaati, 2021 1.38 [0.45; 4.20]
Metcovid, 2020 1.19 [0.56; 2.49]
Ranjbar, 2021 0.36 [0.13; 0.97]
RECOVERY dexamethasone, 2020 0.77 [0.62; 0.95]
0.82 [0.61 ; 1.08 ] CAPE-COVID, 2020, Jamaati, 2021, Metcovid, 2020, Ranjbar, 2021, RECOVERY dexamethasone, 2020 5 17% 5,891 moderate not evaluable radiologic improvement (14-day)detailed results Jamaati, 2021 4.89 [1.15; 20.79]
4.89 [1.15 ; 20.79 ] Jamaati, 2021 1 0% 50 NA not evaluable viral clearance detailed results Tang X, 2020 1.78 [1.06; 3.00]
1.78 [1.06 ; 3.00 ] Tang X, 2020 1 0% 86 NA not evaluable viral clearance (time to event analysis only)detailed results Tang X, 2020 1.78 [1.06; 3.00]
1.78 [1.06 ; 3.00 ] Tang X, 2020 1 0% 86 NA not evaluable ICU admissiondetailed results Tang X, 2020 1.00 [0.13; 7.45]
1.00 [0.13 ; 7.45 ] Tang X, 2020 1 0% 86 NA not evaluable serious adverse eventsdetailed results CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
0.53 [0.17 ; 1.62 ] CODEX (Tomazini), 2020 1 0% 299 NA not evaluable superinfectiondetailed results CAPE-COVID, 2020 0.81 [0.49; 1.34]
Metcovid, 2020 0.98 [0.65; 1.47]
0.91 [0.66 ; 1.25 ] CAPE-COVID, 2020, Metcovid, 2020 2 0% 542 moderate not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 02:02 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 522,582,666,1149,1150,737,544,733
- roots T: 290
